Is Mono Pharmacare overvalued or undervalued?

Sep 23 2025 08:06 AM IST
share
Share Via
As of September 22, 2025, Mono Pharmacare is fairly valued with a PE ratio of 13.15, significantly lower than its peers, indicating strong growth potential despite a year-to-date stock decline of 30.01%.
As of 22 September 2025, Mono Pharmacare's valuation grade has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued, with a price-to-earnings (PE) ratio of 13.15, a price-to-book value of 1.30, and an EV to EBITDA ratio of 12.25. These ratios suggest that the company is positioned competitively within its industry.

In comparison to its peers, Mono Pharmacare's PE ratio is significantly lower than that of Sun Pharma (34.24) and Divi's Lab (70.06), both categorized as expensive. Additionally, its PEG ratio of 0.49 indicates strong growth potential relative to its earnings. While the company's stock has underperformed the Sensex year-to-date, with a decline of 30.01% compared to the Sensex's gain of 6.59%, the recent grade change and valuation metrics suggest that Mono Pharmacare may present an attractive investment opportunity moving forward.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Why is Mono Pharmacare falling/rising?
Dec 13 2025 01:24 AM IST
share
Share Via
How has been the historical performance of Mono Pharmacare?
Nov 28 2025 10:44 PM IST
share
Share Via
Why is Mono Pharmacare falling/rising?
Nov 20 2025 12:18 AM IST
share
Share Via
How has been the historical performance of Mono Pharmacare?
Nov 18 2025 11:03 PM IST
share
Share Via
Is Mono Pharmacare overvalued or undervalued?
Nov 11 2025 08:14 AM IST
share
Share Via
Is Mono Pharmacare overvalued or undervalued?
Nov 07 2025 08:14 AM IST
share
Share Via
Why is Mono Pharmacare falling/rising?
Oct 16 2025 12:03 AM IST
share
Share Via
Most Read
Galada Finance Ltd is Rated Sell
19 minutes ago
share
Share Via
Gujarat Cotex Ltd is Rated Sell
19 minutes ago
share
Share Via
Beryl Drugs Ltd is Rated Sell
19 minutes ago
share
Share Via
Nutech Global Ltd is Rated Hold
19 minutes ago
share
Share Via